Neumora Therapeutics annual free cash flow
2022
2023
Neumora Therapeutics Free Cash Flow (FCF) History (NMRA)
Neumora Therapeutics reported −$163.4M in free cash flow for fiscal 2023, a decrease of $48.0M from the previous fiscal year.
View full Neumora Therapeutics company overviewNeumora Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-12-31 | −$163.4M | −$48.0M | — | — |
| 2022 | 2022-12-31 | −$115.4M | — | — | — |
Neumora Therapeutics quarterly free cash flow
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$51.5M | — | — | — |
| Q3 2023 | 2023-09-30 | −$47.8M | — | — | — |
| Q2 2023 | 2023-06-30 | −$31.0M | — | — | — |
| Q1 2023 | 2023-03-31 | −$33.1M | — | — | — |
Neumora Therapeutics free cash flow growth trends
Neumora Therapeutics's latest reported quarter, Q4 2023, generated −$51.5M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Neumora Therapeutics source filings ↗